AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Estrella shares surge 10.70% premarket as STARLIGHT-1 trial advances to Phase II with strong safety and efficacy data.
ByAinvest
Thursday, Dec 4, 2025 8:29 am ET1min read
Estrella Immunopharma (NASDAQ: ESLA) surged 10.70% in premarket trading after announcing that its EB103 CD19-redirected ARTEMIS® T-cell therapy advanced to Phase II of the STARLIGHT-1 trial following a favorable safety review. An independent Data Safety Monitoring Board confirmed no treatment-related serious adverse events in nine patients, including high-risk individuals ineligible for existing CD19 therapies, and highlighted a 100% complete response rate in the high-dose cohort. The milestone underscores EB103’s potential as a best-in-class therapy with broader applicability to relapsed/refractory B-cell NHL patients, including high-risk subgroups. The Phase II expansion will evaluate safety and efficacy at the recommended dose, with data expected to inform pivotal trial strategies. The news directly relates to the company’s core clinical-stage biopharmaceutical development and positions EB103 as a differentiated candidate in the CAR-T space.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet